OncoCyte (NYSEAMERICAN:OCX) Shares Down 36.8%

OncoCyte Corp (NYSEAMERICAN:OCX)’s stock price traded down 36.8% on Wednesday . The company traded as low as $2.36 and last traded at $2.52. 2,866,256 shares traded hands during mid-day trading, an increase of 260% from the average session volume of 796,241 shares. The stock had previously closed at $3.99.

A number of equities research analysts recently issued reports on the stock. Zacks Investment Research downgraded shares of OncoCyte from a “buy” rating to a “hold” rating in a report on Wednesday, April 17th. Chardan Capital restated a “buy” rating and issued a $8.00 target price on shares of OncoCyte in a report on Tuesday, April 2nd. Finally, Benchmark set a $7.00 target price on shares of OncoCyte and gave the company a “buy” rating in a report on Friday, June 7th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. OncoCyte presently has a consensus rating of “Buy” and an average target price of $6.00.

OncoCyte (NYSEAMERICAN:OCX) last announced its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.01.

Several hedge funds have recently made changes to their positions in OCX. Perkins Capital Management Inc. acquired a new stake in OncoCyte in the first quarter valued at $99,000. Virtu Financial LLC acquired a new stake in OncoCyte in the first quarter valued at $114,000. Spark Investment Management LLC acquired a new stake in OncoCyte in the first quarter valued at $159,000. Finally, Emerald Mutual Fund Advisers Trust acquired a new stake in OncoCyte in the first quarter valued at $9,836,000.

OncoCyte Company Profile (NYSEAMERICAN:OCX)

OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer.

Read More: What can cause a stock to outperform?

Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.